Synapse - Meghan Thompson

Results (56)

First results from a phase 1, first-in-human study of the Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies (BGB-16673-101)

Meeting Abstract

Seymour, J. F.; Cheah, C. Y.; Parrondo, R.; Thompson, M. C.; Stevens, D. A.; Lasica, M.; Wang, M. L.; Kumar, A.; Trotman, J.; Alwan, M.; more...
Blood (2023)

Fulltext@MSK | Save

A first-in-human phase 1 trial of NX-2127, a first-in-class Bruton's tyrosine kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed/refractory B cell malignancies

Meeting Abstract

Danilov, A.; Tees, M. T.; Patel, K.; Wierda, W. G.; Patel, M.; Flinn, I. W.; Latif, T.; Ai, W. Y.; Thompson, M. C.; Wang, M. L.; more...
Blood (2023)

Fulltext@MSK | Save

A first-in-human phase 1 study of ABBV-525, a small-molecule MALT1 inhibitor, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Meeting Abstract

Sochacki, A. L.; Burger, J. A.; Ludwig, C.; Assaily, W.; Munasinghe, W.; Pappano, W.; Greenberg, E.; Will, C.; Thompson, M. C.
Blood (2023)

Fulltext@MSK | Save

A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation

Meeting Abstract

Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
Blood (2023)

Fulltext@MSK | Save

Outcomes of patients with richter transformation without prior chemoimmunotherapy for CLL/SLL: An international multicenter retrospective study

Meeting Abstract

Kittai, A. S.; Huang, Y.; Miller, S.; Allan, J. N.; Bhat, S. A.; Bond, D. A.; Brander, D. M.; Byrd, J. C.; Chavez, J. C.; Chong, E. A.; more...
Blood (2023)

Fulltext@MSK | Save

Chemotherapy-sparing induction followed by consolidation and maintenance with blinatumomab and concurrent oral tyrosine kinase inhibitor therapy for newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: Primary endpoint results from the BLISSPHALL study

Meeting Abstract

Geyer, M. B.; Mascarenhas, J.; Smith, M.; Pascual, S.; Shah, A.; Silvestrone, M. R.; Czaplinska, T.; Johnson, K.; Thompson, M. C.; Park, J. H.
Blood (2023)

Fulltext@MSK | Save

Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades

Meeting Abstract

Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
Blood (2023)

Fulltext@MSK | Save

Pirtobrutinib monotherapy in patients with relapsed/refractory B-cell malignancies intolerant to prior covalent BTK inhibitor

Meeting Abstract

Munir, T.; Shah, N. N.; Wang, M.; Brown, J. R.; Patel, K.; Woyach, J.; Wierda, W. G.; Ujjani, C. S.; Eyre, T. A.; Zinzani, P. L.; more...
British Journal of Haematology (2023)

Fulltext@MSK | Save

Non-covalent Bruton's tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia

Review

Montoya, S.; Thompson, M. C.
Cancers (2023)

Fulltext@MSK | Save

Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL

Meeting Abstract

Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Meghan Caitlin Thompson

Results (56)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Review

Meeting Abstract